The value of approved therapies for pulmonary arterial hypertension
- 1 June 2007
- journal article
- editorial
- Published by Elsevier in American Heart Journal
- Vol. 153 (6) , 889-890
- https://doi.org/10.1016/j.ahj.2007.03.001
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- A meta-analysis of trials of pulmonary hypertension: A clinical condition looking for drugs and research methodologyAmerican Heart Journal, 2007
- Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary HypertensionCirculation, 2006
- Exercise Training in Pulmonary HypertensionCirculation, 2006
- Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial HypertensionCirculation, 2005
- Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic reviewEuropean Heart Journal, 2005
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- The 6-minute walk test: How important is the learning effect?American Heart Journal, 2003
- Beraprost therapy for pulmonary arterial hypertensionJournal of the American College of Cardiology, 2003
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992